Bektur, C.Kayir, F.Nurgozhin, T.2017-12-132017-12-132014-11-01C. Bektur, F. Kayir, T. Nurgozhin, PMS37 - Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Page A37910983015https://www.sciencedirect.com/science/article/pii/S1098301514045562http://nur.nu.edu.kz/handle/123456789/2860The purpose of present study was to evaluate the cost-effectiveness of tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime horizon in Kazakhstan.enOpen Access - the content is available to the general publicPMS37 Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in KazakhstanArticleCopyright © 2014 Published by Elsevier Inc.